Significant differences in cellular and plasma biomarkers between newly diagnosed BOS and patients with respiratory tract infections in univariate analysis
| . | Newly diagnosed BOS . | Infection and cGVHD . | Infection and no cGVHD . | P BOS vs infection and cGVHD . | P BOS vs infection and no cGVHD . |
|---|---|---|---|---|---|
| Number of patients | 46 | 29 | 17 | ||
| BAFF, ng/mL | 7.3 | 4.6 | 3.7 | .08 | .03 |
| CD19+ B cells × 106/L | 146 | 220 | 330 | .04 | .0001 |
| CD19+ B cells, % of lymphocytes | 10.2 | 12 | 19.2 | .5 | .0021 |
| Ratio ng BAFF/CD19+ × 103 B cells | 0.18 | 0.08 | 0.01 | .08 | .02 |
| CD19+CD21low B cells, % of CD19+ B cells | 25.5 | 12.35 | 7.8 | .001 | .0002 |
| IgG, mg/dL | 533 | 895 | 961 | .0007 | .0004 |
| CD4+ T cells, % of lymphocytes | 23.6 | 21.6 | 23.4 | .4 | .9 |
| . | Newly diagnosed BOS . | Infection and cGVHD . | Infection and no cGVHD . | P BOS vs infection and cGVHD . | P BOS vs infection and no cGVHD . |
|---|---|---|---|---|---|
| Number of patients | 46 | 29 | 17 | ||
| BAFF, ng/mL | 7.3 | 4.6 | 3.7 | .08 | .03 |
| CD19+ B cells × 106/L | 146 | 220 | 330 | .04 | .0001 |
| CD19+ B cells, % of lymphocytes | 10.2 | 12 | 19.2 | .5 | .0021 |
| Ratio ng BAFF/CD19+ × 103 B cells | 0.18 | 0.08 | 0.01 | .08 | .02 |
| CD19+CD21low B cells, % of CD19+ B cells | 25.5 | 12.35 | 7.8 | .001 | .0002 |
| IgG, mg/dL | 533 | 895 | 961 | .0007 | .0004 |
| CD4+ T cells, % of lymphocytes | 23.6 | 21.6 | 23.4 | .4 | .9 |